Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma

Stanciu, Adina Elena; Zamfir-Chiru-Anton, Adina; Stanciu, Mihai; Stoian, Anca Pantea; Jinga, Viorel; Nițipir, Cornelia; Bucur, Alexandru; Pituru, Teodora S; Arsene, Andreea Letiția; Drăgoi, Cristina Manuela; Hainăroşie, Răzvan; Nicolae, Alina; Gherghe, Mirela; Gheorghe, Dan Cristian; Spandidos, Demetrios A.; Tsatsakis, Aristidis; Papasavva, Maria; Drakoulis, Nikolaos

doi:10.3892/ol.2019.11215

Cited by 18 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In this study, median of serum MLT in OSCC patients amounted 13.01 pg/ml (95% CI: 10.08-15.14). These results signi cantly differ from those obtained by Stanciu et al in a study on serum MLT levels in OSCC patients [42]. This group of authors obtained high serum MLT levels at 7 a.m. in the healthy control group (median 47.6 pg/ml; interquartile range: 37.7-66.4; age 57 ± 7 years of age).…”

Section: Discussioncontrasting

confidence: 86%

Salivary Melatonin in Oral Squamous Cell Carcinoma Patients: A Cross-sectional Study

Salarić

Karmelić

Lovrić

et al. 2020

Preprint

View full text Add to dashboard Cite

BACKGROUND: Around 55% of oral squamous cell carcinoma (OSCC) patients are diagnosed in the advanced stage. Poor sleep quality has been associated as a potential risk factor for several malignancies, including head and neck cancers. Melatonin’s role in circadian rhythm is well documented, as are its’ anti-oxidant, oncostatic and anti-inflammatory properties. The purpose of this study is to determine salivary melatonin (MLT) levels in OSCC patients, compare the salivary MLT levels with those in healthy individuals and compare the salivary and serum levels in OSCC patients. Furthermore, the aim is to evaluate sleep quality and to investigate the potential relationship between sleep quality and salivary MLT levels in OSCC patients. METHODS: Unstimulated and stimulated saliva were sampled from patients with T1N0M0 and T2N0M0 OSCC (N=34) and 33 sex and age matched healthy subjects. Serum samples were taken from 11 OSCC patients. Detailed medical history was taken before sampling and sleep quality measured using Pittsburgh Sleep Quality Index (PSQI) questionnaire. RESULTS: Melatonin levels in UWS and SWS were significantly higher in the OSCC group. Sleep quality was significantly lower in patients with OSCC (U=249.50; P = 0.0001). ROC analysis was found to be significant (P <0.001) in evaluating the MLT concentration limit in diagnosing OSCC. CONCLUSIONS: The expected relationship between sleep quality and salivary MLT levels in OSCC patients was not observed. Salivary melatonin could present a potential OSCC biomarker. However, larger prospective studies should validate the clinical utility of MLT as an OSCC biomarker.

show abstract

Section: Discussioncontrasting

confidence: 86%

Salivary Melatonin in Oral Squamous Cell Carcinoma Patients: A Cross-sectional Study

Salarić

Karmelić

Lovrić

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…PTC + AIT patients had positive TgAb antibody titers. The exclusion criteria were as follows: (i) age under 18 years; (ii) acute infection, burning, pulmonary, hepatic or renal impairment; (iii) ongoing treatment with steroidal or non-steroidal anti-inflammatory drugs; (iv) ongoing treatment with antibiotics from the tetracycline group, especially doxycycline (known as MMP inhibitors) [ 19 ]. For each enrolled patient, a detailed medical and drug history was obtained.…”

Section: Methodsmentioning

confidence: 99%

TNF-α May Exert Different Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer with/without Autoimmune Thyroiditis

Gheorghe

Stanciu

Zamfirescu

et al. 2021

Cancers

View full text Add to dashboard Cite

Autoimmune thyroiditis (AIT) may impair radioiodine (131I) uptake in papillary thyroid cancer (PTC). Finding the mechanisms that govern immune cells during 131I therapy of PTC with concomitant AIT (PTC + AIT) could provide a rationale. Our study aimed to evaluate the effects of 131I on anti-thyroglobulin antibodies (TgAb), matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor TIMP-1 and tumor necrosis factor-α (TNF-α) and its receptors TNFR1 and TNFR2, in PTC and PTC + AIT patients. Peripheral blood was collected from 56 female patients with PTC and 32 with PTC + AIT before and 4 days after 131I (3.7 GBq). The serum levels of TgAb, MMP-9, TIMP-1, TNF-α, TNFR1 and TNFR2 were measured by ELISA. The mean radioactivity of blood samples collected after 131I intake was higher in the PTC + AIT group than in PTC (p < 0.001). In the PTC + AIT group, TNF-α/TNFR1 and TNF-α/TNFR2 ratios decreased by 0.38-fold and 0.32-fold after 131I and were positively correlated with the MMP-9/TIMP-1 ratio (r = 0.48, p = 0.005, and r = 0.46, p = 0.007). In the PTC group, TNF-α/TNFR1 and TNF-α/TNFR2 ratios increased by 3.17-fold and 3.33-fold and were negatively correlated with the MMP-9/TIMP-1 ratio (r = −0.62, p < 0.001 and r = −0.58, p < 0.001). Our results demonstrate that TNF-α may exert different antitumor effects in response to 131I therapy depending on the patient’s immune profile.

show abstract

“…The ROC curves were plotted using as a variable the value of MMP-9, TIMP-1, or MMP-9/TIMP-1 ratio for patients admitted to the emergency department compared to the healthy controls, and as a classification criterion, the TBSA burn <25%. The AUC is an overall summary of diagnostic accuracy as follows: AUC >0.9, excellent diagnostic accuracy; AUC between 0.7 and 0.9, good diagnostic accuracy; AUC between 0.5 and 0.7, poor diagnostic accuracy; AUC <0.5, lack of diagnostic value of the biomarker (20). ROC curves have determined cut-off values for optimal sensitivity and specificity.…”

Section: Methodsmentioning

confidence: 99%

Clinical significance of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in the first phase of burn trauma evolution

et al. 2021

Self Cite

View full text Add to dashboard Cite

No prospective study has specifically examined the serum levels of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in the early shock phase of burn-injured patients. Thus, we aimed to detect early changes, activity dynamics, and the predictive value of MMP-9, TIMP-1, and the MMP-9/TIMP-1 ratio to better understand the early repair mechanisms for the development of future therapies for patients with thermal burns. Twenty-five patients with a total body surface area (TBSA) affected by burn <25%, and 30 healthy subjects were enrolled in the study. Serum levels of MMP-9 and TIMP-1 were determined by the ELISA method. Our results showed that MMP-9 concentrations increased immediately after injury and remained on a plateau. In contrast, TIMP-1 showed an upward trend throughout the 7-day study period, and the time course of the MMP-9/TIMP-1 ratio followed the inverse dynamics of TIMP-1. Analysis of the areas under the receiver operating characteristic (ROC) curves (AUC) showed that patients with burn wounds tended to have a MMP-9 value higher than 421.5 ng/ml (AUC= 0.979), TIMP-1 value higher than 231.6 ng/ml (AUC= 0.908), and MMP-9/TIMP-1 ratio higher than 2.31 (AUC= 0.959) (P<0.001). Our findings suggest that although the variations in the two biomarkers were different regarding the time of the initial insult, their ratio is a specific and sensitive indicator of burn evolutivity in patients with a TBSA affected by a burn <25%.

show abstract

Clinical significance of serum melatonin in predicting the severity of oral squamous cell carcinoma

Cited by 18 publications

References 35 publications

Salivary Melatonin in Oral Squamous Cell Carcinoma Patients: A Cross-sectional Study

Salivary Melatonin in Oral Squamous Cell Carcinoma Patients: A Cross-sectional Study

TNF-α May Exert Different Antitumor Effects in Response to Radioactive Iodine Therapy in Papillary Thyroid Cancer with/without Autoimmune Thyroiditis

Clinical significance of serum matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 in the first phase of burn trauma evolution

Contact Info

Product

Resources

About